Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
12
pubmed:dateCreated
2009-12-28
pubmed:abstractText
The therapeutic use of monoclonal antibodies is growing exponentially. Our knowledge on antibody structure, in particular that of IgG1, largely used in the clinic, has progressed remarkably. However, some formidable challenges still remain to be confronted, among which the increase of a yet-limited antibody efficacy, the lowering of the frequency of serious clinical adverse events, and the establishment of pre-clinical models that can be reliably extrapolated to humans represent major goals. The selection of relevant target antigens with regard to the pathology to be treated and to the expected effects of the antibody used is also a critical parameter. Facing these challenges, the amazing molecular plasticity of antibodies, as well as new antibody engineering approaches based on the most recent insights on the structure and biology of antibodies and their targets represent areas of research that will make monoclonal antibodies remarkable drugs for human health in a near future.
pubmed:language
fre
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
0767-0974
pubmed:author
pubmed:issnType
Print
pubmed:volume
25
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1011-9
pubmed:meshHeading
pubmed-meshheading:20035672-Animals, pubmed-meshheading:20035672-Antibodies, Monoclonal, pubmed-meshheading:20035672-Antibody Specificity, pubmed-meshheading:20035672-Antigen-Antibody Reactions, pubmed-meshheading:20035672-Antigens, Neoplasm, pubmed-meshheading:20035672-Antigens, Surface, pubmed-meshheading:20035672-Complementarity Determining Regions, pubmed-meshheading:20035672-Cytokines, pubmed-meshheading:20035672-Drug Delivery Systems, pubmed-meshheading:20035672-Epitopes, pubmed-meshheading:20035672-Humans, pubmed-meshheading:20035672-Immunoconjugates, pubmed-meshheading:20035672-Immunoglobulin Fab Fragments, pubmed-meshheading:20035672-Immunoglobulin Fc Fragments, pubmed-meshheading:20035672-Mice, pubmed-meshheading:20035672-Neoplasms, pubmed-meshheading:20035672-Protein Engineering, pubmed-meshheading:20035672-Risk Assessment
pubmed:year
2009
pubmed:articleTitle
[Antibodies: better knowledge for a better use].
pubmed:affiliation
Laboratoire français du fractionnement et des biotechnologies, Les Ulis, France. Inserm U872, Paris, F-75006 France.
pubmed:publicationType
Journal Article, English Abstract, Review